Christine Alewine

Christine Alewine Christine Campo Alewine is an American oncologist and biologist researching immunotoxin therapeutics in pancreatic cancer. She is an investigator at the National Cancer Institute. Provided by Wikipedia
Showing 1 - 7 results of 7 for search 'Christine Alewine', query time: 0.03s Refine Results
  1. 1
    Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci

    Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci by Jian Xu, Mayrel Palestino Dominguez, Christine Alewine

    Published 2022-03-01
    Get full text
    Article
  2. 2
    Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors

    Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors by Brendan L. Hagerty, Guillaume J. Pegna, Jian Xu, Chin-Hsien Tai, Christine Alewine

    Published 2020-06-01
    Get full text
    Article
  3. 3
    Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

    Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment by Xianyu Zhang, Yunkai Yu, Cody J. Peer, Rebekah Landsman, Nebojsa Skorupan, Liang Cao, Christine Alewine

    Published 2022-07-01
    Get full text
    Article
  4. 4
    Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice.

    Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice. by Jingli Zhang, Tapan K Bera, Wenhai Liu, Xing Du, Christine Alewine, Raffit Hassan, Ira Pastan

    Published 2014-01-01
    Get full text
    Article
  5. 5
    Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors

    Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors by Salma El-Behaedi, Rebekah Landsman, Michael Rudloff, Emily Kolyvas, Rakan Albalawy, Xianyu Zhang, Tapan Bera, Keith Collins, Serguei Kozlov, Christine Alewine

    Published 2018-10-01
    Get full text
    Article
  6. 6
    Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

    Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel by Guillaume Joe Pegna, Min‐Jung Lee, Cody J. Peer, Mehwish I. Ahmad, David J. Venzon, Yunkai Yu, Akira Yuno, Seth M. Steinberg, Liang Cao, William D. Figg, Renee N. Donahue, Raffit Hassan, Ira Pastan, Jane B. Trepel, Christine Alewine

    Published 2023-02-01
    Get full text
    Article
  7. 7
    Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

    Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers by Nebojsa Skorupan, Cody J. Peer, Xianyu Zhang, Hyoyoung Choo-Wosoba, Mehwish I. Ahmad, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Yunkai Yu, Guillaume Joe Pegna, Seth M. Steinberg, Shelley S. Kalsi, Liang Cao, William D. Figg, Jane B. Trepel, Ira Pastan, David FitzGerald, Christine Alewine

    Published 2024-04-01
    Get full text
    Article

Search Tools: